Clinical Trials

88 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04901702 2026-04-13

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Phase 1/2 Recruiting

90 enrolled

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02693535 2026-04-02

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Gynecologic

Endometrial Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

111 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03968406 2026-03-11

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

24 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT04170946 2026-03-05

Talazoparib

24 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

45 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT05873192 2025-12-23

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT06844383 2025-10-29

TALENT

126 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04678362 2025-09-22

TALASUR

50 enrolled

Carcinoma, Transitional Cell

NCT03990896 2025-08-07

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

30 enrolled

Breast

Breast Neoplasms

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05071937 2025-06-22

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer